3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Polycystic Ovary Syndrome
7
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms
3
Breast Neoplasms
3
Leukoplakia, Oral
2
Erythroplasia
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Prediabetic State
1
Posterior Fossa Ependymal Tumor
1
Pleural Effusion, Malignant
1
Ovarian Neoplasms
1
Obesity
1
Neoplasms by Site
1
Mouth Neoplasms
1
Metabolic Diseases
1
Melanoma
1
Medulloblastoma
1
Insulin Resistance
1
Infertility
1
Hyperplasia
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Drug-drug Interaction,SHR3680
1
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
cabozantinib
5
Everolimus
5
pembrolizumab
4
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
tivozanib
1
surufatinib
1
repotrectinib
1
peposertib
1
pazopanib
1
entrectinib
1
belinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Metformin
×
90 days
×
Clear all
No trials found.